The Mounjaro Rebound Effect: What Happens When You Stop

Written by: the Medetone Medical Team

Medically reviewed by: Dr Abdullah

Reading time: 6 minutes  ·  Guidance verified: September 2026

The Mounjaro rebound effect is one of the most common concerns among people considering treatment, and one of the most poorly explained online. The honest answer is that weight regain after stopping is well documented, it has been measured in a trial designed specifically to test it, and it has a clear biological explanation. It is not a sign that the medicine failed or that your body has been damaged. This guide covers what the evidence actually shows, why regain happens, and what influences how much. Mounjaro is a prescription-only medicine and this article is informational.

Key facts at a glance 

• Average loss before stopping: 20.9% over 36 weeks
• Regain after switching to placebo: 14.0% over the following year
• Loss with continued treatment: a further 5.5%
• Maintained at least 80% of their loss: around 90% who continued, 16.6% who stopped

What the rebound effect actually means

In everyday use, “rebound” suggests weight bouncing back above where you started. That is not what the trial data shows. What happens is closer to a gradual return toward your previous weight, not an overshoot past it.

This distinction matters because it changes the decision. The Mounjaro rebound effect is better understood as the loss of an ongoing treatment effect than as a penalty for having taken the medicine. When treatment stops, the biological changes that made eating less feel manageable stop too.

What the evidence shows

The clearest data comes from a trial designed for exactly this question. Participants first took tirzepatide for 36 weeks, losing an average of 20.9% of their body weight. They were then split into two groups: one continued, one switched to placebo.

The contrast is stark, and it is the single most useful number in this whole discussion: nearly 90% of those who continued maintained most of their weight loss, compared with roughly one in six of those who stopped.

Two things are worth noting. The regain happened gradually over about a year, not immediately. And those who stopped still finished below their original starting weight, even after substantial regain.

Continue vs stop comparison

Why the rebound effect happens

The Mounjaro rebound effect has a straightforward mechanism, and understanding it removes a lot of the anxiety around it.

While you are taking it, tirzepatide activates the GIP and GLP-1 receptors, which reduces appetite, slows gastric emptying and quiets the constant background pull toward food. Those effects depend entirely on the medicine being present. Once you stop, the drug clears from your system over several weeks, appetite signalling returns to its previous pattern, and hunger comes back to roughly where it was before.

On top of that, the body responds to weight loss itself with adaptations that push toward regain: appetite-regulating hormones shift, and energy expenditure falls as body mass decreases. These are normal physiological responses to losing weight, not specific to this medicine, and they are part of why maintaining weight loss by any method is difficult.

Put together: the medicine was doing work that your biology does not take over automatically when it stops.

Is it “rebound” or is it a chronic condition?

This is the reframe that clinicians consider most important. Obesity is classified as a chronic, relapsing condition, comparable in that respect to high blood pressure or type 2 diabetes.

Nobody describes blood pressure rising after stopping antihypertensives as a “rebound effect”. It is simply what happens when treatment for an ongoing condition ends. The same logic applies here. The Mounjaro rebound effect is not a flaw in the medicine; it reflects the fact that the underlying condition has not disappeared. Our guide on what happens when you stop weight loss medication explores this further.

This is why treatment is generally framed as long-term therapy with periodic review rather than a short course with a finish line.

Can you stop without rebound?

This is the most searched follow-up question, and the honest answer is nuanced: some regain is likely, but the amount is not fixed.

Several factors appear to influence it:

• Whether lifestyle changes were built during treatment. The medicine makes eating less feel achievable. If that period is used to establish eating patterns and activity that can continue independently, there is something left in place when the pharmacological support ends.

• Muscle mass. Rapid weight loss can include lean tissue, and lower muscle mass means lower energy expenditure. Adequate protein intake and resistance training during treatment are the standard countermeasure, and they matter most at the point of stopping.

• How the treatment ends. Stopping abruptly, without a plan, leaves the largest gap. A planned, clinically supervised reduction with follow-up gives more room to adjust.

• Whether support continues afterwards. Regain happens over months, so monitoring after stopping is when it is actually detected and addressed.

What does not help is stopping on your own without telling your prescriber. That removes exactly the support that makes a difference.

What this means for your decision

If you are weighing up treatment, the useful question is not “will I regain weight if I stop?” but “what is my plan for the long term?”

For some people the answer is continued treatment, potentially at a maintenance dose. For others it is a supervised step down combined with established habits and ongoing monitoring. Both are legitimate. What is not advisable is starting without having thought about it, then stopping abruptly when supply, cost or circumstances change.

Any decision to stop, pause or change dose belongs with your prescriber. If you would like to discuss a long-term plan, you can start an assessment with a licensed clinician. Patients in the UK can explore treatment through Medetone UK or our partner service Rightangled, and patients in the United States through Medetone US.

Frequently asked questions

Does Mounjaro have a rebound effect?

Weight regain after stopping is well documented. In trial data, people who stopped regained 14.0% over the following year, while those who continued lost a further 5.5%.

Will I end up heavier than when I started?

Typically no. Trial participants who stopped still finished below their original starting weight despite substantial regain.

How quickly does weight return?

Gradually, over roughly a year, rather than immediately. The medicine clears over several weeks and appetite returns before the scale moves much.

How can I stop without regaining weight?

Some regain is likely, but a planned, supervised reduction, maintained protein intake and resistance training, established eating habits and continued monitoring all influence how much.

Do I have to take Mounjaro forever?

Not necessarily, but it is designed as a long-term treatment with periodic review. Your prescriber reassesses at intervals and decides with you.

In summary

The Mounjaro rebound effect is real, measurable and explainable. Trial data shows an average 14.0% regain over a year after stopping, against a further 5.5% loss for those who continued. It happens because appetite regulation returns to baseline once the medicine clears, alongside the body's normal adaptations to weight loss. It is not an overshoot above your starting weight, and it is not a failure of the treatment. The practical response is to treat weight management as long-term from the outset, and to make any decision to stop a planned clinical one rather than an abrupt personal one.

Medical information: this article is for information only and does not replace diagnosis, prescription or medical advice. Mounjaro is a prescription-only medicine. Never stop or change your dose without speaking to your prescriber.

References 

AEMPS, Agencia Española de Medicamentos y Productos Sanitarios (Spain): https://www.aemps.gob.es

ANSM, Agence nationale de sécurité du médicament (France): https://ansm.sante.fr

AIFA, Agenzia Italiana del Farmaco (Italy): https://www.aifa.gov.it

CBG-MEB, College ter Beoordeling van Geneesmiddelen (Netherlands): https://www.cbg-meb.nl

BfArM, Bundesinstitut für Arzneimittel und Medizinprodukte (Germany): https://www.bfarm.de

European Medicines Agency, Mounjaro EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro